Juno Therapeutics (JUNO) Misses Q3 EPS by 12c, Offers Guidance

Juno Therapeutics (NASDAQ: JUNO) reported Q3 EPS of ($0.53), $0.12 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.6 million, versus $0 reported last year.

2015 Financial Guidance

Juno continues to expect 2015 cash burn, excluding cash inflows or outflows from business development activities and litigation, to be at the higher end of its guidance of between $125 million and $150 million.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Morgan Stanley upgrades Robinhood, sees 43% upside
• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line